Weight gain and menstrual abnormalities between users of Depo-provera and Noristerat

Treatment of sex offenders with Depo-Provera.

Medroxyprogesterone acetate (MPA) is capable of reducing male testosterone blood levels with a corresponding reduction in sexual interest and activity. An attempt to evaluate its effectiveness with court committed sexual offenders was made with eight subjects each serving as his own control by alternating Depo-Provera injections for 16 weeks with saline injections for a corresponding 16 weeks. ...

Depo-Provera--ethical issues in its testing and distribution.

Ethical issues relating to the use of the injectable contraceptive in developed and developing countries alike involve public policy decisions concerning both criteria for testing a new drug and individual choices about using a specific form of contraception approved for national distribution. Drug testing consists of an important but still evolving set of procedures. Depo-Provera is not qualit...

Medroxyprogesterone acetate (Depo-Provera) and bone mineral density loss.

Depot medroxyprogesterone (Depo-Provera) and risk of breast cancer.

OBJECTIVE To determine whether use of the injectable contraceptive depot medroxyprogesterone acetate (Depo-Provera) affects the risk of breast cancer in women. DESIGN A population based case-control study. SETTING Nationwide community study. SUBJECTS 891 Women aged 25-54 with newly diagnosed breast cancer were compared with 1864 women selected at random from the electoral rolls. INTERVE...

Determining risk between Depo-Provera use and increased uterine bleeding in obese and overweight women.

BACKGROUND Millions of women worldwide use depot medroxyprogesterone acetate (DMPA) for contraception. Common side effects include bleeding irregularities and weight gain. This study examines whether a relation exists between DMPA use in obese and overweight women and increased uterine bleeding. METHODS Medical record data were gathered retrospectively from three family medicine clinics, docu...